Fierce Pharma Asia—Eisai's reduced Aduhelm role; Chinese biotechs' US delisting risks; Zai Lab's new COO from Lilly

Eisai has decided to exit its supporting role for Biogen's Alzheimer's drug Aduhelm. Chinese companies including several biotechs face potential U.S.

Related Keywords

,Fierce Pharma Asia ,Disai ,Aduhelm ,Securities And Exchange Commission ,Zai Lab ,Biogen ,Beigene ,Hutchmed ,China ,Eli Lilly ,Astellas ,Omen 039s Health ,Menopause ,Chugai ,Ultomiris Ravulizumab Cwvz ,Patent Lawsuits ,Shionogi ,Covid 19 ,Antivirals ,Plant Expansion ,Macleods ,Drug Recall ,Stevanato Group ,India ,Asia ,Fierce Pharma Homepage ,Pharma ,